ID

24891

Beschrijving

Study ID: 101468/166 Clinical Study ID: SKF-101468/166 Study Title: A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Parkinson Disease

Trefwoorden

Versies (3)
  1. 22-08-17 22-08-17 -
  2. 22-08-17 22-08-17 -
  3. 04-09-17 04-09-17 -
Geüploaded op

22 augustus 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY-NC 3.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

randomization determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166

Engels

randomization determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166

1 Formulieren  
Administrative Data
Beschrijving

Administrative Data

Alias
UMLS CUI-1
C1320722
Patient Initials
Beschrijving

patient's initials

Datatype

text

Alias
UMLS CUI [1]
C2986440
Patient No.
Beschrijving

patient number

Datatype

integer

Alias
UMLS CUI [1]
C1830427
Date of Visit
Beschrijving

date of visit

Datatype

date

Alias
UMLS CUI [1]
C1320303
RANDOMIZATION AND COHORT ASSIGNMENT
Beschrijving

RANDOMIZATION AND COHORT ASSIGNMENT

Alias
UMLS CUI-1
C0034656
After review of all eligibility criteria is the patient eligible for the study?
Beschrijving

patient eligible for clinical trial

Datatype

text

Alias
UMLS CUI [1]
C1302261
Randomization Number
Beschrijving

randomization numb

Datatype

integer

Alias
UMLS CUI [1]
C2986235
Terug naar het begin van de pagina

Similar models

randomization determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
Administrative Data
C1320722 (UMLS CUI-1)
patient's initials
Item
Patient Initials
text
C2986440 (UMLS CUI [1])
patient number
Item
Patient No.
integer
C1830427 (UMLS CUI [1])
date of visit
Item
Date of Visit
date
C1320303 (UMLS CUI [1])
Item Group
RANDOMIZATION AND COHORT ASSIGNMENT
C0034656 (UMLS CUI-1)
Item
After review of all eligibility criteria is the patient eligible for the study?
text
C1302261 (UMLS CUI [1])
patient eligible for clinical trial
Code List
After review of all eligibility criteria is the patient eligible for the study?
CL Item
Yes - Please telephone the Central Randomization Center to enroll the patient. Record the assigned (1)
CL Item
Randomization Number and check the appropriate box to indicate the assigned Cohort in the (Randomization Number and check the appropriate box to indicate the assigned Cohort in the)
CL Item
section below. (section below.)
CL Item
No - Record the reason for Screen Failure on the "Patient Screening/Enrollment Log." (2)
randomization numb
Item
Randomization Number
integer
C2986235 (UMLS CUI [1])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial